GCWB1176 Evaluates the Effectiveness and Safety of Immune Function

Inclusion criteria

• At the time of screening, 19 or 75 years
• A person with a peripheral blood leukocyte level measured in Visit 1, 3x10^3 cells/μl or more, 8x10^3 cells/μl
• Those who are more than one of the following standards

• Those who had more than twice within one year of visiting 1 year.

• {Common cold, acute tonsillitis, acute pharyngitis, acute laryngitis, acute rhinitis, etc.

• Those who have stomatitis more than twice within 1 year of visit

• Those who had Herpes Zoster infection within 1 year of visit
• Those with a stress awareness scale (PSS) 16 or more
• A person who agrees to participate in this human application test before the start of the human test and writes a written consent form

Exclusion criteria

• Those who are currently treating drugs due to underlying disease, etc.
• Hypertension patients (systolic blood pressure 140 mmHg or higher or dichotomous blood pressure 90 mmHg or higher, human application test target 10 minutes stabilized)
• Patients with diabetes with an fasting blood sugar at least 126 mg/dL or administering urine disease (oral blood sugar, insulin, etc.)
• Those who are 0.1 UIU/mL or less, or 10 UIU/mL or more
• Those who have vaccinated vaccines (influenza, corona, shingles that can affect immunity) within 3 months of visiting 1
• A disease that can affect immune responses such as adult -like and rhinitis
• AST (GOT) or ALT (GPT) is three times more than the normal upper limit of the embodiment
• Those who are 1.5 times more than the normal upper limit of Creatinine
• Those who administered steroids, antibiotics, immunosuppressants, and gastric acid inhibitors within 1 month of visit.
• Visit 1 person who consumes vitamins, health functional foods that can affect immunity within 2 weeks of visiting
• A person who has administered or consumed lactic acid bacteria products (4 or more times a week) within 2 weeks of visiting within 2 weeks of visit.
• Those who complain of severe gastrointestinal symptoms such as heartburn and indigestion
• Those who are pregnant or have a planning plan for lactation or this human application period
• Those who have participated in other interventional clinical trials (including human application test) within 8 weeks of visit, or plan to participate in other interventional clinical trials (including human application tests) after the beginning of this human application test
• Those who are sensitive or allergic to food ingredients for this human application
• Those who have a BMI (body mass index) of 30 kg/m2 or more
• A person who consumed alcohol within 1 month (30 days) based on 1 visit (man> 210 g/week, woman> 140 g/week)
• Those who judge that the test person is inadequate for other reasons